Effect of Intravesical Instillations on the Human Complement Factor H Related Protein (BTA &lt;i&gt;stat&lt;/i&gt;) Test

Raitanen, Mika; Hellström, Pekka; Marttila, Timo; Korhonen, Heikki; Talja, Martti; Ervasti, J; Tammela, Teuvo L.J.

doi:10.1159/000049810

Cited by 15 publications

(6 citation statements)

References 22 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although protein‐based urine markers such as bladder tumour‐associated antigen (BTA) and NMP22 offer improved sensitivity for detecting low‐grade tumours compared with cytology, sensitivity remained equivalent for high‐grade tumours, with a lower specificity than cytology . Moreover, haematuria, nephrolithiasis, inflammation and intravesical instillation therapies may cause false‐positive results . By contrast, the Xpert BC Monitor succeeded in discriminating between tumour stages, tumour grades, tumour size and number of tumours, with no higher rate of false positivity in patients with previous intravesical instillations in our series.…”

Section: Discussionmentioning

confidence: 99%

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

et al. 2017

View full text Add to dashboard Cite

ObjectivesTo evaluate the diagnostic accuracy of the Xpert Bladder Cancer (BC) Monitor, compared with cystoscopy and cytology in the oncological follow-up of non-muscle-invasive bladder cancer (NMIBC). Material and MethodsA total of 140 patients with a history of NMIBC undergoing routine surveillance at our institution were enrolled prospectively in this study (ISRCTN study registry number 37210907). Urine cytology was evaluated according to the Paris classification system. In addition, urinary specimens were analysed using the Xpert BC Monitor, which measures five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) using real-time PCR. Descriptive analysis, diagnostic accuracy including sensitivity, specificity, positive (PPV) and negative predictive value (NPV), receiver-operating characteristic curve, and area under the curve (AUC) were calculated. ResultsThe overall sensitivity (0. ConclusionIn this study, we report for the first time that the Xpert BC Monitor, a new mRNA-based urine test, outperforms cytology with regard to sensitivity and NPV, even in low-grade and pTa tumours, with no reduction of specificity.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

et al. 2017

View full text Add to dashboard Cite

show abstract

“…48 Past bacille Calmette-Guérin (BCG) therapy, recent intravesical instillation and factors including nicotine, caffeine, acetylsalicylic acid and acetaminophen may also result in false-positive BTA scores. 49,50 Both BTA tests are approved for the surveillance of recurrent bladder cancer.…”

Section: Bladder Tumour Antigen Testmentioning

confidence: 99%

Biomarkers for detection and surveillance of bladder cancer

Budman

Kassouf

Steinberg

2013

CUAJ

126

View full text Add to dashboard Cite

Introduction: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women in Canada. Early detection of tumours is essential for improved prognosis and long-term survival. The standard method for detection and surveillance is cystoscopy together with urine cytology. Cystoscopy is relatively sensitive but is expensive and invasive. Urinary cytology is a noninvasive method that has poor sensitivity but high specificity; it is relied on for the detection of carcinoma in situ. Currently, several urinary based bladder tumour biomarkers with USFDA/Health Canada approval are available commercially, but none have been widely adopted by urologists despite their offering high sensitivity and/or specificity. We present here a review of recent studies evaluating 7 commercial biomarker assays for the detection and/or surveillance of bladder cancer.Results: Sensitivity and specificity ranges, respectively, for each marker were reported as follows: BTA Stat (Polymedco), 52.5%–78.0% and 69.0%–87.1%; BTA Trak (Polymedco), 51%–100% and 73%–92.5%; cytology, 12.1%–84.6% and 78.0%–100%; hematuria dipstick, 47.0%–92.6% and 51.0%–84.0%; NMP22 Bladder Cancer Test (Matritech), 34.6%–100% and 60.0%–95.0%; NMP22 BladderChek (Matritech), 49.5%–65.0% and 40.0%–89.8%;ImmunoCyt/uCyt+ (DiagnoCure), 63.3%–84.9% and 62.0%–78.1%; ImmunoCyt/uCyt+ and cytology, 81.0%–89.3% and 61.0%–77.7%; and UroVysion (Abbott Molecular)/florescence in situ hybridization, 68.6%–100% and 65.0%–96.0%.Conclusion: We find that no currently available bladder cancer urinary marker is sensitive enough to eliminate the need for cystoscopy. In addition, cytology remains integral to the detection of occult cancer. However, owing to their relatively high sensitivities, these markers may be used to extend the period between cystoscopies in the surveillance of patients with transitional cell carcinoma. Further study is required to determine which markers, alone or in panel, would best accomplish this.

show abstract

“…As with NMP22, the presence of haematuria, nephrolithiasis, recent genitourinary instrumentation, inflammation, and other urological malignancies can yield a false‐positive result [19,20]. Recent intravesical BCG therapy also causes false‐positive tests [21]. With the publication of larger studies supporting the use of NMP22, the use of BTA appears to have declined, although exact figures from the USA are not available.…”

Section: Commercially Available Ubbtmmentioning

confidence: 99%